Antineoplaston Therapy | AETNA Coverage Update

Summary: Aetna, a CVS Health company, modified CPB 0240 covering antineoplaston therapy, effective April 14, 2026. Here's what billing teams need to do.

Aetna's antineoplaston therapy coverage policy under CPB 0240 has been updated. This policy governs one of the more contentious areas in oncology billing — a therapy that has sat in "experimental and investigational" territory for decades. The policy does not list specific CPT or HCPCS codes in the available data, so your billing team will need to rely on the full policy document and your internal charge capture protocols to identify affected claims.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna
Policy	Antineoplaston Therapy — CPB 0240
Policy Code	CPB 0240
Change Type	Modified
Effective Date	2026-04-14
Impact Level	Medium
Specialties Affected	Oncology, Hematology/Oncology, Integrative Medicine, Infusion Therapy
Key Action	Review your antineoplaston therapy billing workflows and denial management protocols before April 14, 2026

---

Aetna Antineoplaston Therapy Coverage Criteria and Medical Necessity Requirements 2026

CPB 0240 Aetna is the clinical policy bulletin that controls whether Aetna will reimburse antineoplaston therapy for any enrolled member. The short version: Aetna has treated antineoplaston therapy as experimental and investigational for years. This latest modification doesn't change that fundamental position.

Antineoplaston therapy — developed by Dr. Stanislaw Burzynski — involves peptides and amino acid derivatives administered to treat certain cancers, most notably brain tumors. The therapy has never received FDA approval for general oncology use. That regulatory gap is exactly why payers like Aetna consistently deny it on medical necessity grounds.

The medical necessity bar here is essentially unreachable under current criteria. Aetna's coverage policy for antineoplaston therapy requires peer-reviewed clinical evidence demonstrating safety and efficacy for the proposed indication. No such evidence meeting Aetna's standard currently exists. Billing this therapy and expecting reimbursement is, in almost every case, going to result in claim denial.

What the modification may have addressed — based on the pattern of how Aetna updates CPB policies — is a language refresh, updated clinical evidence citations, or a revision to the list of indications reviewed. Without the full redline from the prior version, you can't know exactly what shifted. That's a real problem. If your practice has any patients currently receiving antineoplaston therapy under an Aetna plan, you need the line-by-line diff of this change before April 14, 2026.

Prior authorization for antineoplaston therapy would be required if it were covered — but since it isn't, any prior auth request your team submits will come back as a denial on experimental/investigational grounds. Don't waste administrative time chasing prior auth for a non-covered service unless you have a specific clinical exception pathway or an active appeals strategy in place.

---

Aetna Antineoplaston Therapy Exclusions and Non-Covered Indications

The core exclusion is broad: Aetna considers antineoplaston therapy experimental and investigational for all indications. That includes brain tumors, other solid tumors, blood cancers, and any other oncology application.

This isn't a case where one indication is covered and others aren't. The entire therapy class is excluded. That matters for your billing team because it means there's no code-level workaround, no modifier strategy, and no documentation pathway that converts this into a covered service under a standard Aetna commercial or Medicare Advantage plan.

The only realistic path to reimbursement for a patient receiving antineoplaston therapy is a clinical exception appeal — and those require very specific clinical circumstances. If your practice is treating a patient under an FDA clinical trial or a compassionate use protocol, talk to your compliance officer before billing. The billing rules for investigational services under clinical trial coverage provisions are different, and getting this wrong creates overpayment risk.

---

Coverage Indications at a Glance

---

Aetna Antineoplaston Therapy Billing Guidelines and Action Items 2026

The effective date is April 14, 2026. Here's what your team needs to do before that date — and after.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Antineoplaston Therapy Under CPB 0240

The available policy data for CPB 0240 does not list specific CPT, HCPCS, or ICD-10 codes. This is not unusual for a policy covering a therapy that lacks FDA approval — there's no standard code set built around antineoplaston administration.

In practice, antineoplaston therapy billing tends to use infusion administration codes and compounded drug codes, depending on how the therapy is administered. However, the policy data does not specify those codes, and we won't invent them here.

What you should do instead:

Contact Aetna provider services directly and ask which codes they track for antineoplaston therapy claims. Ask specifically:

• What CPT or HCPCS codes trigger review under CPB 0240
• Whether any infusion administration codes (96xxx series) are flagged in conjunction with antineoplaston drug billing
• Whether any compounded drug HCPCS codes are associated with this policy

That conversation will give you the actual code-level data you need to update your charge capture and denial routing. It also creates a documented record of your due diligence — which matters if you end up in an audit or overpayment review.

---

What the CPB 0240 Modification Really Means for Your Revenue Cycle

Here's the honest take: for most billing teams, this policy change is low direct financial exposure because antineoplaston therapy is rarely billed through commercial insurance channels. Patients who pursue this treatment typically do so at the Burzynski Clinic, often on a self-pay basis, after exhausting conventional options.

But the practices that do get caught by this policy are usually integrative oncology practices or providers who've agreed to bill for a patient as a courtesy — without fully understanding the coverage policy landscape. Those are the teams that end up with large denied claims, frustrated patients, and compliance headaches.

If your practice is in that category — even occasionally — the April 14, 2026 effective date matters. The modification may have tightened language in ways that close off appeal arguments that previously had some traction. You don't know until you read the diff.

The broader pattern here is worth noting. Aetna has modified CPB 0240 before, and each modification typically adds more specific language about the lack of peer-reviewed evidence. The effect is to make it harder, not easier, to argue for clinical exceptions on appeal. That's the direction this policy has been moving for years.

---